Hyperviscosity in Polycythemia Vera and Other Red Cell Abnormalities

Hau C. Kwaan; Jun Wang

doi:10.1055/s-2003-44552

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2003; 29(5): 451-458
DOI: 10.1055/s-2003-44552

Hyperviscosity in Polycythemia Vera and Other Red Cell Abnormalities

Hau C. Kwaan^1,2 , Jun Wang²

¹Professor, Hematology/Oncology Division, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
²Hematology/Oncology Division, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Abstract

ABSTRACT

Thrombosis is a major cause of mortality and morbidity in polycythemia vera (PV). The wide range of thrombotic events reflects the complex picture in PV. There are multiple factors involved in thrombogenesis in this disease, including increased hematocrit, thrombocytosis, impaired fibrinolytic activity, platelet activation, leukocyte activation, endothelial damage, interactions between platelets and endothelium, various modalities of therapy, and increased in whole-blood viscosity. Among them, the increase in blood viscosity, and hence the impairment of blood flow, is the major factor. In this article, the role of hyperviscosity in PV is reviewed. A high hematocrit occurs under PV and many other conditions with abnormal red blood cell aggregation. The impaired capillary blood flow results in neurological manifestations and increased bleeding risk in PV. Thrombotic complications can also occur in both arteries and veins and manifest as stroke, myocardial infarction, deep vein thrombosis, or pulmonary embolism. The hemodynamic principle is aptly applied in the management of PV. The most important objective is the reduction of the patient's hematocrit.

KEYWORDS

Hyperviscosity - polycythemia vera - red cell aggregation - thrombosis - rheology

Full Text

References

REFERENCES

1 Spivak J L. Polycythemia vera: myths, mechanisms, and management. Blood . 2002; 100 4272-4290
2 Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med . 1995; 123 656-664
3 Berk P D, Goldberg J D, Donovan P B. et al . Therapeutic recommendations in polycythemia vera based on polycythemia vera study protocols. Semin Hematol . 1986; 23 132-143
4 Wasserman L R, Balcerzak S P, Berk P D. et al . Influence of therapy on causes of death in polycythemia vera. Trans Assoc Am Phys . 1981; 94 30-38
5 Donovan P B, Kaplan M E, Goldberg J D. et al . Treatment of polycythemia vera with hydroxyurea. Am J Hematol . 1984; 17 329-334
6 Tatarsky I, Shron R. Management of polycythemia vera with hydroxyurea. Semin Hematol . 1997; 34 24-28
7 Chievitz E, Thiede E. Complications and causes of death in polycythemia vera. Acta Med Scand . 1962; 172 513-523
8 Begg T B, Hearns J B. Components in blood viscosity. The relative contribution of haematocrit, plasma fibrinogen and other proteins. Clin Sci . 1966; 31 87-93
9 Jensen M K, de Nully P B, Lund B V, Nielsen O J, Hasselbalch H C. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol . 2000; 110 116-124
10 Turitto V, Weiss H. Red blood cells: their dual role in thrombus formation. Science . 1976; 207 541-543
11 Vaziri N D. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis . 1999; 33 821-828
12 Kornberg A, Rahimi-Levene N, Yona R, Mor A, Rachmilewitz E A. Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation. Am J Hematol . 1997; 56 5-11
13 Posan E, Ujj G, Kiss A. et al . Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia. Thromb Res . 1998; 90 51-56
14 Lamparter S, Schuermann M, Heidtmann H-H. APC resistance as an additional thrombotic risk factor in a patient suffering from polycythemia vera and recurrent thrombosis. Ann Hematol . 1997; 74 49-50
15 Falanga A, Marchetti M, Evangelista V. et al . Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood . 2000; 96 4261-4266
16 Kwaan H C, Suwanwela N. Inhibitors of fibrinolysis in platelet on polycythemia vera and thrombocytosis. Br J Haematol . 1971; 21 313-322
17 Baskurt O K, Meiselman H J. Blood rheology and hemodynamics. Semin Thromb Hemost . 2003; 29 435-450
18 Wells R E, Merrill E W. Influence of flow properties of blood upon viscosity-hematocrit relationships. J Clin Invest . 1962; 41 1591-1598
19 Streiff M B, Smith B, Spivak J L. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood . 2002; 99 1144-1149
20 Pearson T C, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythemia. Lancet . 1978; 2 1219-1221
21 Pearson T C. Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Semin Thromb Hemost . 1997; 23 433-439
22 Brown G, Giffin H Z. Studies of capillaries and blood volume in polycythemia vera. Am J Med Sci . 1923; 166 489-502
23 Kwaan H C, Harding F, Astrup T. Platelet behavior in small blood vessels in vivo. Thrombosis et Diathesis Haemorrhagica . 1967; 18 207-220
24 Barabas A P, Offen D N, Meinhard E A. The arterial complications of polycythemia vera. Br J Surg . 1973; 60 183-187
25 Pearson T C, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet . 1978; 2 1218-1222
26 Taylor G W, Calo A R. Atherosclerosis of arteries of the lower limb. BMJ . 1962; 1 507-510
27 Murray J F, Escobar E. Circulatory effects of blood viscosity: comparison of methemoglobinemia and anemia. J Appl Physiol . 1968; 25 594-599
28 Massik J, Tang Y L, Hudak M L. et al . Effect of hematocrit on cerebral blood flow with induced polycythemia. J Appl Physiol . 1987; 62 1090-1096
29 Pearson T C. Rheology of the absolute polycythemias. Baillieres Clin Haematol . 1987; 1 637-664
30 Brown M M, Wade J P, Marshall J. Fundamental importance of arterial oxygen content in the regulation of cerebral blood flow in man. Brain . 1985; 108 81-93
31 Mitchell M C, Biotnott J K, Kaufman S, Cameron J L, Maddrey W C. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine . 1982; 61 199-218
32 Dintenfass L. Experiment on "Discovery" STS 51-C. Aggregation of red cells and thrombocytes in heart disease, hyperlipidemia and other conditions. Adv Space Res . 1959; 9 65-69
33 van Haeringen J N, Oosterhuis J A, Terpstre J, Glasius E. Erythrocyte aggregation in relation to diabetic retinopathy. Diabetologia . 1973; 9 20-24
34 Schmid-Schönbein H, Volger E. Red-cell aggregation and red-cell deformability in diabetes. Diabetes . 1976; 25(Suppl 2) 897-902
35 Le Devehat C, Vimcux M, Bondoux G, Khodabandchlou T. Red blood cell aggregation in diabetes mellitus. Int Angiol . 1990; 9 11-15
36 Ziegler O, Guerci B, Muller S. et al . Increased erythrocyte aggregation in insulin dependent diabetes mellitus and its relationship to plasma factors: a multivariate analysis. Metabolism . 1994; 43 1182-1186
37 Dintenfass L, Somer T. On the aggregation of red cells in Waldenström's macroglobulinaemia and multiple myeloma. Microvasc Res . 1975; 9 279-286
38 Razavian S M, Atger V, Giral P. et al . Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men: PCVMETRA group. Arterioscler Thromb Vasc Biol . 1994; 14 361-366
39 Vaya A, Martinez M, Carmena R, Aznar J. Red blood cell aggregation and primary hyperlipoproteinemia. Thromb Res . 1993; 72 119-126
40 Tranquilli A L, Garzetti G G, De Tommaso G. et al . Nifedipine treatment in preeclampsia reverts the increased erythrocyte aggregation to normal. Am J Obstet Gynecol . 1992; 167 942-945
41 Bohler T, Linderkamp O, Leo A, Wingen A M, Scharer K. Increased aggregation with normal surface charge and deformability of red blood cells in children with nephrotic syndrome. Clin Nephrol . 1992; 38 119-124
42 Razavian S M, Del Pino M, Simon A, Levenson J. Increase in erythrocyte disaggregation shear stress in hypertension. Hypertension . 1992; 20 247-252
43 Williams L, Domen R E. Vancomycin-induced red cell aggregation. Transfusion . 1989; 29 23-26
44 Kallio T, Alanen A, Kormano M. The effect of radiographic contrast media on ultrasonically detectable red blood cell aggregation in vitro. Invest Radiol . 1989; 24 789-793
45 Kwaan H C, Levin M, Sakurai S. et al . Digital ischemia and gangrene due to red blood cell aggregation induced by acquired dysfibrinogenemia. J Vasc Surg . 1997; 26 1061-1068
46 Chen S, Eldor A, Barshtein G. et al . Enhanced aggregability of red cells of β-thalassemia major patients. Am J Physiol . 1996; 270 H1951-H1956
47 Obiefima P C. Rouleaux formation in sickle cell traits. J Trop Med . 1991; 94 42-44
48 Palek J, Lux S E. Red cell membrane skeletal defects in hereditary and acquired hemolytic anemias. Semin Hematol . 1983; 20 189-224
49 Wright I G. An electron microscopic study of intravascular agglutination in the cerebral cortex due to Babesia argentina infection. Int J Parasitol . 1972; 2 209-215
50 Miller L H, Usami S, Chien S. Alteration in the rheologic properties of Plasmodium knowlesi-infected red cells: a possible mechanism for capillary obstruction. J Clin Invest . 1971; 50 1451-1455
51 Chien S, Cooper Jr W G, Jan K M. et al . N-acetylneuraminic acid deficiency in erythrocyte membranes: biophysical and biochemical correlates. Blood . 1974; 43 445-460
52 Zarkovic M, Kwaan H C. Correction of hyperviscosity by apheresis. Semin Thromb Hemost . 2003; 29 535-542